Premium
A phase II study of methyl CCNU in the treatment of solid tumors and lymphomas: A Southwest oncology group study
Author(s) -
Tranum Bill L.,
Haut Arthur,
Rivkin Saul,
Weber Edward,
Quagliana Joseph M.,
Shaw Michael,
Tucker William G.,
Smith Frank E.,
Samson Michael,
Gottlieb Jeffrey
Publication year - 1975
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(197504)35:4<1148::aid-cncr2820350420>3.0.co;2-5
Subject(s) - medicine , oncology , lymphoma , toxicity , large cell , chemotherapy , phases of clinical research , head and neck , adenocarcinoma , cancer , gastroenterology , surgery
In March of 1972, the Southwest Oncology Group initiated a Phase II study, No. 7200, utilizing methyl‐CCNU in the treatment of patients with solid tumors and lymphomas. Initially, they received 200 mg/m 2 orally as a single dose every 6 weeks. The dose was subsequently reduced in poor‐risk patients to 150 mg/m 2 . There were 69 responses noted in 675 evaluable patients (10%). The highest response rates were noted in patients with Hodgkin's disease (13/31, 35%), malignant gliomas of the brain (8/29, 28%), anaplastic carcinomas of the lung (5/20, 25%), and squamous cell carcinomas of the head and neck (5/29, 17%). Squamous cell tumors appeared to be more responsive than adenocarcinomas (15% vs. 5%, respectively). Hematologic toxicity was cumulative, and was influenced by dose and prior treatment. There appeared to be no cross‐resistance in patients previously treated with alkylating agents. Methyl‐CCNU is an active antineoplastic agent. Further studies are indicated in order to determine relative effectiveness.